植華集團(01842.HK):新冠疫情或對20財年中期業績產生不利影響
格隆匯2月20日丨植華集團(01842.HK)公佈,集團位於深圳的生產設施、全球開發及供應鏈中心已於2月12日恢復生產和服務。集團位於江西的生產設施已於2月18日恢復生產。
由於長時間停工及員工流動性減少,預計集團將暫時面臨產量下降,加上城市及省份之間的交通限制,若干預定交付亦可能受影響。在此等情況下,集團將繼續實現經調整的生產及交付目標,減輕對集團及其客户的任何不利經濟影響。
公告稱,上述疫情對集團業務營運的影響已超出集團控制範圍,或會對集團截至2020年6月30日止六個月的財務業績產生不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.